NORTAI International Ltd. announced that it will receive CNY 51,741,026 (HKD 56,527,800) in an equity round of funding from returning investor Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) on September 3, 2019. Post closing, the registered capital of the company will increase from CNY 257,907,886 (HKD 281,768,000) to CNY 309,648,912 (HKD 338,295,800) and the investor will retain 100% stake in the company. The transaction was approved by the board of directors of the investor in its 4th meeting of the 22nd directorate. The transaction does not need approval from the shareholders.